ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer

Geneva, Switzerland, 22 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced today new appointments to its Management Team.

Elke Bestel joins ObsEva as Chief Medical Officer & Head of Pharmacovigilance bringing 19 years of experience in pharmaceutical product development.

Prior to joining ObsEva, Elke was the CMO at PregLem, a Swiss based specialty biopharmaceutical company. She was one of the key players in the successful development and European registration of Esmya® (treatment of uterine fibroids). Prior to PregLem, she worked for Galderma, France, where she was responsible for clinical studies as well as development, registration and life-cycle activities of dermatological products (Epiduo®, Soolantra®, Adapalene® and Clindagel®). Before joining Galderma, she worked at the clinical research organization MDS, France where she was responsible for the conduct of clinical studies from Phase I to III.

Elke holds a MD degree from the University of Göttingen, Germany, and received training in gynecology at the Kantonsspital Bruderholz, Switzerland.

Jean-Pierre Gotteland joins ObsEva as Chief Scientific Officer. He has over 20 years’ experience in the pharmaceutical industry in all product development stages particularly in research, preclinical development and early clinical development.

After an early career at Pierre Fabre Medicament (France), Jean-Pierre joined Serono in 1998 (subsequently Merck Serono) where he was responsible for various research and preclinical development programs in the areas of neurology, autoimmune disorders, endocrinology, metabolism and oncology. In 2007, he was one of the first employees to join PregLem, a Swiss based specialty biopharmaceutical company. As VP Non Clinical Development & CMC then Chief Development Officer, he actively contributed to the successful European registration of Esmya® (treatment of uterine fibroids), PregLem’s lead product as well as to the progression of development of product portfolio.

Jean-Pierre holds a PhD in Organic Chemistry from the University Claude Bernard (Lyon, France) and an Engineering Diploma from Ecole Superieure de Chimie Industrielle (Lyon, France). He was a postdoctoral fellow at the University of Berkeley (California, USA), and he is the author and co-author of more than 40 publications and 30 patents.

“I am delighted to welcome Elke and Jean-Pierre at ObsEva, as I had the opportunity to extensively witness their drug development experience and capacity at PregLem. It is also very timely as ObsEva is actively enlarging its portfolio of products in development” stated Ernest Loumaye, CEO and Co-Founder of ObsEva.

About ObsEva

ObsEva is a clinical stage biopharmaceutical company focusing on the development of a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth. Our lead programs target the underserved problems of infertility and preterm labor affecting more and more women worldwide. The ObsEva team’s unique development expertise is supported by top-tier investors in order to build a leading company in pregnancy pharmaceuticals. For more information, please visit www.obseva.com .

Company Contact:

ObsEva CEO Office

Delphine Renaud

Tel: +41 22 552 1550

delphine.renaud@obseva.ch